[go: up one dir, main page]

CY1111285T1 - Θεραπεια αυτοανοσων ασθενειων - Google Patents

Θεραπεια αυτοανοσων ασθενειων

Info

Publication number
CY1111285T1
CY1111285T1 CY20111100242T CY111100242T CY1111285T1 CY 1111285 T1 CY1111285 T1 CY 1111285T1 CY 20111100242 T CY20111100242 T CY 20111100242T CY 111100242 T CY111100242 T CY 111100242T CY 1111285 T1 CY1111285 T1 CY 1111285T1
Authority
CY
Cyprus
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
methods
Prior art date
Application number
CY20111100242T
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1111285T1 publication Critical patent/CY1111285T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Μέθοδοι θεραπείας διαφόρων αυτοάνοσων ασθενειών, όπως είναι η σκλήρυνση κατά πλάκας, η περιφερειακή νευρίτιδα, η οπτική νευρίτιδα, η αμυοτροφική πλάγια σκλήρυνση και η ραγοειδίτιδα, χρησιμοποιώντας συγκεκριμένα παράγωγα αμινο αλκοόλης παρέχονται στην εφεύρεση.
CY20111100242T 2005-09-09 2011-03-01 Θεραπεια αυτοανοσων ασθενειων CY1111285T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
EP06793341A EP1926483B1 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
CY1111285T1 true CY1111285T1 (el) 2015-08-05

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100242T CY1111285T1 (el) 2005-09-09 2011-03-01 Θεραπεια αυτοανοσων ασθενειων

Country Status (28)

Country Link
US (1) US20080200438A1 (el)
EP (2) EP1926483B1 (el)
JP (4) JP5244598B2 (el)
KR (3) KR101476591B1 (el)
CN (1) CN101257899B (el)
AT (1) ATE489948T1 (el)
AU (2) AU2006289100B2 (el)
BR (1) BRPI0615906A2 (el)
CA (2) CA2620554C (el)
CY (1) CY1111285T1 (el)
DE (1) DE602006018629D1 (el)
DK (2) DK2295049T3 (el)
ES (2) ES2357426T3 (el)
IL (2) IL189665A (el)
JO (1) JO2655B1 (el)
MA (1) MA29787B1 (el)
MX (1) MX2008003170A (el)
NO (1) NO20081727L (el)
NZ (2) NZ566137A (el)
PL (2) PL1926483T3 (el)
PT (2) PT2295049E (el)
RU (2) RU2493840C2 (el)
SG (1) SG165364A1 (el)
SI (2) SI1926483T1 (el)
TN (1) TNSN08103A1 (el)
TW (2) TWI372620B (el)
WO (1) WO2007028821A2 (el)
ZA (1) ZA200801694B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1772145B1 (en) 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
ES2615498T3 (es) 2004-10-12 2017-06-07 Kyorin Pharmaceutical Co., Ltd. Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol
KR101297302B1 (ko) * 2005-10-07 2013-08-19 교린 세이야꾸 가부시키 가이샤 2-아미노-1,3-프로판디올 유도체를 유효성분으로 하는간장질환 치료제 및 간장질환 치료방법
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
PL2058317T3 (pl) * 2006-08-08 2014-03-31 Kyorin Seiyaku Kk Aminowa pochodna estru kwasu fosforowego i modulator receptora S1P zawierający ją jako składnik aktywny
WO2008018447A1 (en) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
RU2505288C2 (ru) * 2008-05-20 2014-01-27 Киорин Фармасьютикал Ко., Лтд. Средства поддержания индуцированной ремиссии
CN102119028A (zh) * 2008-08-18 2011-07-06 诺瓦提斯公司 用于治疗脱髓鞘性周围神经病的氨基醇衍生物
BR112012028190A2 (pt) * 2010-05-06 2016-08-02 Novartis Ag tratamento de doenças autoimunes
EP2566473B1 (en) * 2010-05-06 2016-01-06 Novartis AG Dosage regimen of diaryl sulfide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
CA2461212C (en) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
US6963012B2 (en) * 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
BR0314455A (pt) * 2002-09-19 2005-07-26 Kyorin Seiyaku Kk Derivados de aminoálcool, seus sais e agentes imunosupressores
TWI335311B (en) * 2002-09-24 2011-01-01 Novartis Ag Organic compounds
CA2499882C (en) * 2002-09-28 2010-11-09 Mcneil-Ppc, Inc. Modified release dosage form with two cores
CN100344638C (zh) * 2003-02-18 2007-10-24 杏林制药株式会社 氨基膦酸衍生物、其加成盐以及s1p受体调节剂
KR101367574B1 (ko) * 2003-04-08 2014-02-25 미쓰비시 타나베 파마 코퍼레이션 Ｓ1ｐ 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물
TW200505416A (en) * 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
ATE449069T1 (de) * 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
EP1772145B1 (en) * 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2820510A1 (en) 2007-03-15
ES2529724T3 (es) 2015-02-25
HK1149906A1 (en) 2011-10-21
CA2620554C (en) 2013-12-17
NO20081727L (no) 2008-06-06
EP2295049A1 (en) 2011-03-16
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
RU2011111117A (ru) 2012-09-27
AU2006289100B2 (en) 2010-07-22
JP2017019854A (ja) 2017-01-26
WO2007028821A3 (en) 2007-05-03
MA29787B1 (fr) 2008-09-01
PL2295049T3 (pl) 2015-04-30
MX2008003170A (es) 2008-03-18
JP6077265B2 (ja) 2017-02-08
ZA200801694B (en) 2009-09-30
TW200803829A (en) 2008-01-16
RU2008113187A (ru) 2009-10-20
BRPI0615906A2 (pt) 2011-05-31
KR101476451B1 (ko) 2014-12-24
KR20140019033A (ko) 2014-02-13
PT2295049E (pt) 2015-03-02
AU2010224355B2 (en) 2012-03-29
JP2013010802A (ja) 2013-01-17
DK1926483T3 (da) 2011-03-14
IL189665A0 (en) 2008-06-05
TNSN08103A1 (en) 2009-07-14
PT1926483E (pt) 2011-03-03
AU2006289100A1 (en) 2007-03-15
ATE489948T1 (de) 2010-12-15
EP2295049B1 (en) 2014-11-26
TWI372620B (en) 2012-09-21
TWI376223B (en) 2012-11-11
DE602006018629D1 (de) 2011-01-13
SI1926483T1 (sl) 2011-04-29
CA2620554A1 (en) 2007-03-15
NZ566137A (en) 2011-05-27
DK2295049T3 (en) 2015-02-23
JP2015025002A (ja) 2015-02-05
WO2007028821A2 (en) 2007-03-15
EP1926483A2 (en) 2008-06-04
ES2357426T3 (es) 2011-04-26
PL1926483T3 (pl) 2011-05-31
KR20140117704A (ko) 2014-10-07
EP1926483B1 (en) 2010-12-01
TW201034659A (en) 2010-10-01
IL189665A (en) 2014-07-31
JO2655B1 (en) 2012-06-17
NZ588372A (en) 2012-03-30
JP5244598B2 (ja) 2013-07-24
IL233328A0 (en) 2014-08-31
CN101257899A (zh) 2008-09-03
RU2493840C2 (ru) 2013-09-27
AU2010224355A1 (en) 2010-10-14
RU2424795C2 (ru) 2011-07-27
SG165364A1 (en) 2010-10-28
KR20080046231A (ko) 2008-05-26
JP2009507810A (ja) 2009-02-26
CN101257899B (zh) 2012-10-03
SI2295049T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
BRPI0513310A (pt) análogos de tetrapeptìdeo
UA85559C2 (en) Aminobenzophenone compounds
CY1112297T1 (el) Ετεροκυκλικοι αναστολεις της μεκ και μεθοδοι χρησης αυτων
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
EA201070247A1 (ru) Ингибиторы протеасом
WO2006121610A3 (en) Personal care compositions and methods for their use
CY1114916T1 (el) Μεθοδοι
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
ATE425982T1 (de) Thienopyrimidin-derivate als kaliumkanal- inhibitoren
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
SE0301650D0 (sv) Novel compounds
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
NO20053903D0 (no) Nukleotidlipidesterderivater.
BRPI0415355A (pt) triarilimidazóis
ATE399532T1 (de) Medizinische seife
MX2007005615A (es) Agentes para el tratamiento del cabello o la piel que comprenden 3-piridinoles y/o 5-pirimidinoles.
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων
CL2012000172A1 (es) Compuestos derivados de heterociclos nitrogenados, reductores de peptido beta-amiloide; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades de alzheimer, sindrome de down, alteracion cognitiva debil, degeneracion macular relacionada con la edad.